US equities
|
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
INTC
$113.12
▲+0.55%
MU
$1,088.00
▲+4.06%
NVDA
$237.47
▼-0.74%
SNDK
$1,692.42
▲+1.92%
SPCX
$167.60
▼-2.51%
AMD
$645.86
▼-0.55%
AAPL
$336.67
▲+0.91%
TSLA
$377.81
▼-0.75%
INTC
$113.12
▲+0.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tango Therapeutics, Inc. - Common Stock
(NQ:
TNGX
)
21.83
-0.07 (-0.32%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tango Therapeutics, Inc. - Common Stock
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 01, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 11, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Announces Executive Chair Transition
August 06, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Appoints Robert Azelby to Board of Directors
June 22, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
June 09, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Announces Proposed $500 Million Public Offering
June 08, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
June 08, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 13, 2026
From
Tango Therapeutics, Inc.
Via
GlobeNewswire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2026
From
Tango Therapeutics Sub, Inc
Via
GlobeNewswire
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
April 15, 2026
From
Tango Therapeutics Sub, Inc
Via
GlobeNewswire
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
March 19, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
November 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 07, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Announces Discontinuation of TNG348 Program
May 23, 2024
From
Tango Therapeutics
Via
Business Wire
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 08, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
March 18, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Tango Therapeutics to Participate in Upcoming Investor Conferences
March 06, 2024
From
Tango Therapeutics, Inc.
Via
Business Wire
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs
March 08, 2023
From
The Briscoe Law Firm, PLLC
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tango Therapeutics, Inc (TNGX) Investigation
February 21, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
December 15, 2022
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021
September 30, 2021
From
Tango Therapeutics, Inc.
Via
Business Wire
